{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:20:49Z","timestamp":1760782849845},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.ctrv.2006.04.009","type":"journal-article","created":{"date-parts":[[2006,6,13]],"date-time":"2006-06-13T10:50:55Z","timestamp":1150195855000},"page":"325-332","source":"Crossref","is-referenced-by-count":11,"title":["Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients"],"prefix":"10.1016","volume":"32","author":[{"given":"Emilio","family":"Bria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Cuppone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmondo","family":"Terzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cognetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Carlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2006.04.009_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2006.04.009_bib2","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women","volume":"1","author":"Fossati","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2006.04.009_bib4","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2006.04.009_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/cncr.21339","article-title":"New Aromatase Inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma","volume":"104","author":"Carlini","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.04.009_bib6","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib7","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib8","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior effi-cacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib9","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of Letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib10","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/jco.2005.23.16_suppl.602","article-title":"New aromatase inhibitors (AIs) as 1st-line endocrine therapy (ET) in metastatic breast cancer (MBC): a pooled analysis of 3238 women from 8 phase III trials","volume":"23","author":"Carlini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2006.04.009_bib11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1677\/erc.1.00857","article-title":"Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer","volume":"12","author":"Normanno","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2006.04.009_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","article-title":"Mechanisms of tamoxifen resistance","volume":"11","author":"Ring","year":"2004","journal-title":"Endocr-Relat Cancer"},{"key":"10.1016\/j.ctrv.2006.04.009_bib13","first-page":"1081","article-title":"Estrogen-dependent tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"350","author":"Benz","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2006.04.009_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"The ATAC Trialists\u2019 Group","year":"2005","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ctrv.2006.04.009_bib15","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2006.04.009_bib16","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2006.04.009_bib17","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1200\/JCO.2001.19.22.4209","article-title":"Sequential tamoxifen and aminoglutetimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian Cooperative Study","volume":"19","author":"Boccardo","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib18","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2006.04.009_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.04.120","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole (ITA) trial","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2006.04.009_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(01)00453-3","article-title":"Meta-analyses of randomized clinical trials in oncology","volume":"2","author":"Pignon","year":"2001","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2006.04.009_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/cncr.20757","article-title":"Taxanes with anthracyclines as first line chemotherapy for metastatic breast cancer: pooled analysis of 2805 patients","volume":"103","author":"Bria","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.04.009_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1634\/theoncologist.7-3-181","article-title":"Interpreting measures of treatment effect in cancer clinical trials","volume":"7","author":"Douglas-Case","year":"2002","journal-title":"The Oncologist"},{"key":"10.1016\/j.ctrv.2006.04.009_bib24","series-title":"Survival analysis: a practical approach","author":"B Parmar","year":"1995"},{"key":"10.1016\/j.ctrv.2006.04.009_bib25","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2006.04.009_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/jco.2005.23.16_suppl.526","article-title":"Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib27","unstructured":"Coombes RC, Hall E, Snowdon CF, et al. The intergroup exemestane study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. In: Proceedings SABCS 2005. abs. 18."},{"key":"10.1016\/j.ctrv.2006.04.009_bib28","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(05)74803-0","article-title":"ATAC trial update","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.ctrv.2006.04.009_bib29","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1200\/JCO.2005.03.7416","article-title":"Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2006.04.009_bib30","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1200\/JCO.2005.02.964","article-title":"Optimising adjuvant endocrine therapy in postmenopausal women with early stage breast cancer: a decision analysis","volume":"23","author":"Punglia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib31","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/jco.2005.23.16_suppl.658","article-title":"Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer","volume":"23","author":"Cuzick","year":"2005","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2006.04.009_bib32","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/JCO.2005.03.7374","article-title":"Computer modeling is no substitute for randomized clinical trials for decision making in early breast cancer hormonal therapy","volume":"23","author":"Vakaet","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.04.009_bib33","unstructured":"Jonat W, Gnant M, Boccardo F, et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. In: Proceedings SABCS 2005. abs. 18."},{"issue":"11","key":"10.1016\/j.ctrv.2006.04.009_bib34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J Gen Intern Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T05:53:33Z","timestamp":1555653213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737206000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0305737206000843"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2006.04.009","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}